Description: Burning Rock Biotech develops cancer diagnostic treatment based on deoxyribonucleic acid (DNA). The company provides tumor gene detection, liquid biopsy, hereditary tumor gene detection, tumor benign, and precision clinical trail for lung cancer, breast cancer, colorectal cancer, prostatic cancer, thyroid cancer, and hereditary tumors. Burning Rock Biotech was founded in January 2014, and is based in Guangzhou, China with additional locations in Beijing and Shanghai, China.
Home Page: www.brbiotech.com
BNR Technical Analysis
No. 5, Xingdao Ring Road North
Guangzhou,
510005
China
Phone:
86 20 3403 7871
Officers
| Name | Title |
|---|---|
| Dr. Shaokun Chuai | Chief Scientific Officer & Director |
| Mr. Yusheng Han | Founder, Chairman & CEO |
| Mr. Jinxiang Li | CFO, Compliance Officer & Director |
| Dr. Zhihong Zhang | Chief Technology Officer |
| Mr. Hao Liu | Sr. Advisor |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.545 |
| Price-to-Sales TTM: | 0.5153 |
| IPO Date: | 2020-06-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 1394 |